AOD-9604 in Surfside — Fat Loss Peptide Research Guide
AOD-9604 research guide for Surfside. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Surfside looking to source AOD-9604, the foundational reality is that this compound is available only through an online research supply market. This concentration of supply in online vendors is ultimately a quality advantage — top vendors distinguish themselves through rigorous testing in ways brick-and-mortar outlets simply cannot. A credible AOD-9604 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. This guide takes Surfside researchers through that evaluation process and explains what quality documentation for AOD-9604 should look like.
AOD-9604: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Surfside comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade AOD-9604
The most reliable path to quality AOD-9604 is community research first — peptide forums maintain informal vendor reputation databases that are more trustworthy than marketing materials. When reviewing a AOD-9604 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are below the threshold for research use. For Surfside researchers evaluating vendors with limited track records: a modest first purchase to test the product before placing larger orders is what experienced peptide researchers consistently do. Store lyophilised AOD-9604 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order AOD-9604 — ships to Surfside
COA-verified · International tracking · Research grade
AOD-9604 is available for research use only and is not approved for human consumption by the FDA or equivalent regulatory bodies — all information here is educational. Proper handling of AOD-9604 requires careful sterile procedure — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and temperature control throughout the entire workflow. Endotoxin testing in the AOD-9604 COA is absolutely required — gram-negative bacterial endotoxins can trigger dangerous immune responses at very low concentrations, and no discount compensates for this missing data. PubMed are the primary literature resources for AOD-9604 research; favour indexed journal publications over preprints over case reports or anecdotal evidence.
Frequently Asked Questions
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
